Standard preparations are calibrated by spectroscopic measurements and stored in a state suitable for use over an extended period of time.

- **Hybridisation conditions.** The stringency of hybridisation conditions is such as to ensure specific hybridisation between probes and standard DNA preparations and the drug substances must not interfere with hybridisation at the concentrations used.

**Sequence-independent techniques**

Suitable procedures include: detection of sulphonated cytosine residues in single-stranded DNA (where DNA is immobilised on a filter and cytosines are derivatised in situ, before detection and quantitation using an antibody directed against the sulphonated group); detection of single-stranded DNA using a fragment of single-stranded DNA bound to a protein and an antibody of this protein. Neither procedure requires the use of specific host or vector DNA as an assay standard. However, the method used must be validated to ensure parallelism with the DNA standard used, linearity of response and non-interference of either the drug substance or excipients of the formulation at the dilutions used in the assay.

**IDENTIFICATION, TESTS AND ASSAY**

The requirements with which the final product (bulk material or dose form) must comply throughout its period of validity, as well as specific test methods, are stated in the individual monograph.

**01/2008:2034**

**SUBSTANCES FOR PHARMACEUTICAL USE**

Corpora ad usum pharmaceuticum

The statements in this monograph are intended to be read in conjunction with individual monographs on substances in the Pharmacopoeia. Application of the monograph to other substances may be decided by the competent authority.

**DEFINITION**

Substances for pharmaceutical use are any organic or inorganic substances that are used as active substances or excipients for the production of medicinal products for human or veterinary use. They may be obtained from natural sources or produced by extraction from raw materials, fermentation or synthesis.

This monograph does not apply to herbal drugs, herbal drug preparations or extracts, which are the subject of separate general monographs [Herbal drugs (1433), Herbal drug preparations (1434), Extracts (0765)].

Where medicinal products are manufactured using substances for pharmaceutical use of human or animal origin, the requirements of chapter 5.1.7. *Viral safety* apply.

Substances for pharmaceutical use may be used as such or as starting materials for subsequent formulation to prepare medicinal products. Depending on the formulation, certain substances may be used either as active substances or as excipients. Solid substances may be compacted, coated, granulated, powered to a certain fineness or processed in other ways. Processing with addition of excipients is permitted only where this is specifically stated in the Definition of the individual monograph.

**Substance for pharmaceutical use of special grade.**

Unless otherwise indicated or restricted in the individual monographs, a substance for pharmaceutical use is intended for human and veterinary use, and is of appropriate quality for the manufacture of all dosage forms in which it can be used.

**Polymorphism.** Individual monographs do not usually specify crystalline or amorphous forms, unless bioavailability is affected. All forms of a substance for pharmaceutical use comply with the requirements of the monograph, unless otherwise indicated.

**PRODUCTION**

Substances for pharmaceutical use are manufactured by procedures that are designed to ensure a consistent quality and comply with the requirements of the individual monograph or approved specification.

The provisions of general chapter 5.10 apply to the control of impurities in substances for pharmaceutical use. Whether or not it is specifically stated in the individual monograph that the substance for pharmaceutical use:

- is a recombinant protein or another substance obtained as a direct gene product based on genetic modification, where applicable, the substance also complies with the requirements of the general monograph on *Products of recombinant DNA technology* (0784);

- is obtained from animals susceptible to transmissible spongiform encephalopathies other than by experimental challenge, where applicable, the substance also complies with the requirements of the general monograph on *Products with risk of transmitting agents of animal spongiform encephalopathies* (1483);

- is a substance derived from a fermentation process, whether or not the micro-organisms involved are modified by traditional procedures or recombinant DNA (rDNA) technology, where applicable, the substance complies with the requirements of the general monograph on *Products of fermentation* (1468).

If solvents are used during production, they are of suitable quality. In addition, their toxicity and their residual level are taken into consideration (5.4). If water is used during production, it is of suitable quality.

If substances are produced or processed to yield a certain form or grade, that specific form or grade of the substance complies with the requirements of the monograph. Certain functionality-related tests may be described to control properties that may influence the suitability of the substance and subsequently the properties of dosage forms prepared from it.

**Powdered substances** may be processed to obtain a certain degree of fineness (2.9.12).

**Compacted substances** are processed to increase the particle size or to obtain particles of a specific form and/or to obtain a substance with a higher bulk density.

**Coated active substances** consist of particles of the active substance coated with one or more suitable excipients.

**Granulated active substances** are particles of a specified size and/or form produced from the active substance by granulation directly or with one or more suitable excipients.

If substances are processed with excipients, these excipients comply with the requirements of the relevant monograph or, where no such monograph exists, the approved specification.
CHARACTERS
The statements under the heading Characters (e.g. statements about the solubility or a decomposition point) are not to be interpreted in a strict sense and are not requirements. They are given for information. Where a substance may show polymorphism, this may be stated under Characters in order to draw this to the attention of the user who may have to take this characteristic into consideration during formulation of a preparation.

IDENTIFICATION
Where under Identification an individual monograph contains subdivisions entitled First identification and Second identification, the test or tests that constitute the First identification may be used in all circumstances. The test or tests that constitute the Second identification may be used for identification, provided it can be demonstrated that the substance is fully traceable to a batch certified to be used for identification, provided it can be demonstrated that the substance is traceable to a batch certified to be used for identification.

TESTS
Polymorphism (5.9). If the nature of a crystalline or amorphous form imposes restrictions on its use in preparations, the nature of the specific crystalline or amorphous form is identified, its morphology is adequately controlled and its identity is stated on the label.

Related substances. Unless otherwise prescribed or justified and authorised, organic impurities in active substances are to be reported, identified wherever possible, and qualified as indicated in Table 2034.-1. Specific thresholds may be applied for impurities known to be unusually potent or to produce toxic or unexpected pharmacological effects.

If the individual monograph does not provide suitable control for a new impurity, a suitable test for control must be developed and included in the specification for the substance.

The requirements above do not apply to biological and biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, products of fermentation and semi-synthetic products derived therefrom, to crude products of animal or plant origin or herbal products.

Residual solvents are limited according to the principles defined in chapter 5.4, using general method 2.4.24 or another suitable method. Where a quantitative determination of a residual solvent is carried out and a test for loss on drying is not carried out, the content of residual solvent is taken into account for calculation of the assay content of the substance, the specific optical rotation and the specific absorbance.

Microbiological quality. Individual monographs give acceptance criteria for microbiological quality wherever such control is necessary. Table 5.1.4.-2. – Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use in chapter 5.1.4. Microbiological quality of pharmaceutical preparations gives recommendations on microbiological quality that are of general relevance for substances subject to microbial contamination. Depending on the nature of the substance and its intended use, different acceptance criteria may be justified.

Sterility (2.6.1). If intended for use in the manufacture of sterile dosage forms without a further appropriate sterilisation procedure, or if offered as sterile grade, the substance for pharmaceutical use complies with the test for sterility.

Bacterial endotoxins (2.6.14). If offered as bacterial endotoxin-free grade, the substance for pharmaceutical use complies with the test for bacterial endotoxins. The limit and test method (if not gelation method A) are stated in the individual monograph. The limit is calculated in accordance with Test for bacterial endotoxins: guidelines (2.6.14), unless a lower limit is justified from results from production batches or is required by the competent authority. Where a test for bacterial endotoxins is prescribed, a test for pyrogens is not required.

Pyrogens (2.6.8). If the test for pyrogens is justified rather than the test for bacterial endotoxins and if a pyrogen-free grade is offered, the substance for pharmaceutical use complies with the test for pyrogens. The limit and test method are stated in the individual monograph or approved by the competent authority. Based on appropriate test validation for bacterial endotoxins and pyrogens, the test for bacterial endotoxins may replace the test for pyrogens.

Additional properties. Control of additional properties (e.g. physical characteristics, functionality-related characteristics) may be necessary for individual manufacturing processes or formulations. Grades (such as sterile, endotoxin-free, pyrogen-free) may be produced with a view to manufacture of preparations for parenteral administration or other dosage forms and appropriate requirements may be specified in an individual monograph.

ASSAY
Unless justified and authorised, contents of substances for pharmaceutical use are determined. Suitable methods are used.

LABELLING
In general, labelling is subject to supranational and national regulation and to international agreements. The statements under the heading Labelling therefore are not comprehensive and, moreover, for the purposes of the Pharmacopoeia only those statements that are necessary to demonstrate compliance or non-compliance with the monograph are mandatory. Any other labelling statements are included as recommendations. When the term ‘label’ is used in the Pharmacopoeia, the labelling statements may appear on the container, the package, a leaflet accompanying the package or a certificate of analysis accompanying the article, as decided by the competent authority.

Where appropriate, the label states that the substance is:
– intended for a specific use;
– of a distinct crystalline form;

<table>
<thead>
<tr>
<th>Use</th>
<th>Maximum daily dose</th>
<th>Reporting threshold</th>
<th>Identification threshold</th>
<th>Qualification threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human use or human and veterinary use</td>
<td>≤ 2 g/day</td>
<td>&gt; 0.05 per cent</td>
<td>&gt; 0.10 per cent or a daily intake of &gt; 1.0 mg (whichever is the lower)</td>
<td>&gt; 0.15 per cent or a daily intake of &gt; 1.0 mg (whichever is the lower)</td>
</tr>
<tr>
<td>Human use or human and veterinary use</td>
<td>&gt; 2 g/day</td>
<td>&gt; 0.03 per cent</td>
<td>&gt; 0.05 per cent</td>
<td>&gt; 0.05 per cent</td>
</tr>
<tr>
<td>Veterinary use only</td>
<td>Not applicable</td>
<td>&gt; 0.1 per cent</td>
<td>&gt; 0.2 per cent</td>
<td>&gt; 0.5 per cent</td>
</tr>
</tbody>
</table>
-- of a specific degree of fineness;
-- compacted;
-- coated;
-- granulated;
-- sterile;
-- free from bacterial endotoxins;
-- free from pyrogens;
-- containing gliding agents.

Where applicable, the label states:
-- the degree of hydration,
-- the name and concentration of any added substance (for example, an antimicrobial preservative or an antioxidant).

Where an active substance is processed with addition of an excipient or excipients, the label states the excipient(s) used and the content of active substance and excipient(s).

VACCINES FOR HUMAN USE
Vaccina ad usum humanum

For a combined vaccine, where there is no monograph to cover a particular combination, the vaccine complies with the monograph for each individual component, with any necessary modifications approved by the competent authority.

DEFINITION
Vaccines for human use are preparations containing substances capable of inducing a specific and active immunity in man against an infecting agent or the toxin or the antigen elaborated by it. They shall have been shown to have acceptable immunogenic activity in man with the intended vaccination schedule. They may contain an adjuvant.

Vaccines for human use may contain: organisms inactivated by chemical or physical means that maintain adequate immunogenic properties; living organisms that are naturally avirulent or that have been treated to attenuate their virulence whilst retaining adequate immunogenic properties; antigens extracted from the organisms or secreted by them or produced by genetic engineering; the antigens may be used in their native state or may be detoxified by chemical or physical means and may be aggregated, polymerised or conjugated to a carrier to increase their immunogenicity.

Terminology used in monographs on vaccines for human use is defined in chapter 5.2.1.

Bacterial vaccines are suspensions of various degrees of opacity in colourless or almost colourless liquids, or may be freeze-dried. The concentration of living or inactivated bacteria is expressed in terms of International Units of opacity or, where appropriate, is determined by direct cell count or, for living bacteria, by viable count.

Bacterial toxoids are prepared from toxins by diminishing their toxicity to a non-detectable level or by completely eliminating it by physical or chemical procedures whilst retaining adequate immunogenic properties. The toxoids are obtained from selected strains of micro-organisms. The method of production is such that the toxoid does not revert to toxin. Toxoids may be liquid or freeze-dried. They may be purified and adsorbed. Adsorbed toxoids are suspensions of white or grey particles dispersed in colourless or pale yellow liquids and may form a sediment at the bottom of the container.

Viral vaccines are prepared from viruses grown in animals, in fertilised eggs, in suitable cell cultures or in suitable tissues or by culture of genetically engineered cells. They are liquids that vary in opacity according to the type of preparation or may be freeze-dried. Liquid preparations and freeze-dried preparations after reconstitution may be coloured if a pH indicator such as phenol red has been used in the culture medium.

PRODUCTION

General provisions. The production method for a given product must have been shown to yield consistently batches comparable with the batch of proven clinical efficacy and safety in man. Requirements for production including in-process testing are included in individual monographs. Where justified and authorised, certain tests may be omitted where it can be demonstrated, for example by validation studies, that the production process consistently ensures compliance with the test.

Unless otherwise justified and authorised, vaccines are produced using a seed-lot system. The methods of preparation are designed to maintain adequate immunogenic properties, to render the preparation harmless and to prevent contamination with extraneous agents.

Where vaccines for human use are manufactured using materials of human or animal origin, the general requirements of chapter 5.1.7. Viral safety apply in conjunction with the more specific requirements relating to viral safety in this monograph, in chapters 5.2.2. Chicken flocks free from specified pathogens for the production and quality control of vaccines, 5.2.3. Cell substrates for the production of vaccines for human use and 2.6.16. Tests for extraneous agents in viral vaccines for human use, and in individual monographs.

Unless otherwise justified and authorised, in the production of a final lot of vaccine, the number of passages of a virus, or the number of subcultures of a bacterium, from the master seed lot shall not exceed that used for production of the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

Vaccines are as far as possible free from ingredients known to cause toxic, allergic or other undesirable reactions in man. Suitable additives, including stabilisers and adjuvants may be incorporated. Penicillin and streptomycin are not used at any stage of production nor added to the final product; however, master seed lots prepared with media containing penicillin or streptomycin may, where justified and authorised, be used for production.

Consistency of production is an important feature of vaccine production. Monographs on vaccines for human use give limits for various tests carried out during production and on the final lot. These limits may be in the form of maximum values, minimum values or maximum and minimum tolerances around a given value. While compliance with these limits is required, it is not necessarily sufficient to ensure consistency of production for a given vaccine. For relevant tests, the manufacturer must therefore define for each product a suitable action or release limit or limits to be applied in view of the results found for batches tested clinically and those used to demonstrate consistency of production. These limits may be subsequently refined on a statistical basis in the light of production data.

Substrates for propagation. Substrates for propagation comply with the relevant requirements of the Pharmacopoeia (5.2.2, 5.2.3) or in the absence of such requirements with those of the competent authority. Processing of cell banks and subsequent cell cultures is done under aseptic conditions.